• PegBio will hold an extraordinary general meeting in Hangzhou, Zhejiang province, China, on November 12, 2026.
• Shareholders will consider reallocating approximately RMB 95.5 million from PB-119 clinical development projects to its commercialization and post-market studies.
• Proposals also include removing KPMG as auditor for 2026 and appointing Rongcheng (Hong Kong) CPA as its replacement.
• The proposed auditor change would reduce annual audit fees by approximately 56.7%, from RMB 3 million to RMB 1.3 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pegbio Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261023-12381980), on October 23, 2026, and is solely responsible for the information contained therein.